Clinical Pre-screening Protocol for Ovarian Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Ovarian Cancer
Interventions
DEVICE

Drug Response Predictor® (DRP)

A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.

Trial Locations (5)

73104

OU Health Stephenson Cancer Center, Oklahoma City

98122

Swedish Center for Research and Innovation, Seattle

02215

Dana-Farber Cancer Institute, Boston

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

Unknown

Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London

Sponsors
All Listed Sponsors
collaborator

Amarex Clinical Research

OTHER

lead

Allarity Therapeutics

INDUSTRY

NCT03877796 - Clinical Pre-screening Protocol for Ovarian Cancer | Biotech Hunter | Biotech Hunter